UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.237-250

2017

Volltextzugriff (PDF)

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

Molecules (Basel, Switzerland), 2018-08, Vol.23 (8), p.2041

2018

Volltextzugriff (PDF)

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity

Archives of biochemistry and biophysics, 2017-11, Vol.633, p.23-28

2017

Volltextzugriff (PDF)

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

Cardiovascular toxicology, 2010-03, Vol.10 (1), p.1-8

2010

Volltextzugriff (PDF)

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

Cardiovascular toxicology, 2020-08, Vol.20 (4), p.380-389

2020

Volltextzugriff (PDF)

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)

Journal of inorganic biochemistry, 2014-08, Vol.137, p.22-30

2014

Volltextzugriff (PDF)

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs

Cardiovascular toxicology, 2018-12, Vol.18 (6), p.557-568

2018

Volltextzugriff (PDF)

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Cardiovascular toxicology, 2017-07, Vol.17 (3), p.297-306

2017

Volltextzugriff (PDF)

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)

Journal of inorganic biochemistry, 2013-09, Vol.126, p.1-6

2013

Volltextzugriff (PDF)

Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F

Free radical biology & medicine, 2007-10, Vol.43 (8), p.1132-1144

2007

Volltextzugriff (PDF)

Total Synthesis of Isoprekinamycin: Structural Evidence for Enhanced Diazonium Ion Character and Growth Inhibitory Activity toward Cancer Cells

Organic letters, 2007-07, Vol.9 (15), p.2915-2918

2007

Volltextzugriff (PDF)

Dexrazoxane use in the prevention of anthracycline extravasation injury

Future oncology (London, England), 2006-02, Vol.2 (1), p.15-20

Hasinoff, Brian B

2006

Volltextzugriff (PDF)

Expression of a stress‐induced hemoglobin affects NO levels produced by alfalfa root cultures under hypoxic stress

The Plant journal : for cell and molecular biology, 2003-09, Vol.35 (6), p.763-770

2003

Volltextzugriff (PDF)

Class-1 hemoglobins, nitrate and NO levels in anoxic maize cell-suspension cultures

Planta, 2004-05, Vol.219 (1), p.66-72

2004

Volltextzugriff (PDF)

Cadmium is a catalytic inhibitor of DNA topoisomerase II

Journal of inorganic biochemistry, 2011-06, Vol.105 (6), p.833-838

2011

Volltextzugriff (PDF)

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

Cardiovascular toxicology, 2007-06, Vol.7 (2), p.140-144

2007

Volltextzugriff (PDF)

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

Free radical biology & medicine, 2003-12, Vol.35 (11), p.1469-1479

2003

Volltextzugriff (PDF)

The intracellular iron sensor calcein is catalytically oxidatively degraded by iron(II) in a hydrogen peroxide-dependent reaction

Journal of inorganic biochemistry, 2003-06, Vol.95 (2), p.157-164

Hasinoff, Brian B.

2003

Volltextzugriff (PDF)

The iron chelator Dp44mT does not protect myocytes against doxorubicin

Journal of inorganic biochemistry, 2009-07, Vol.103 (7), p.1093-1101

2009

Volltextzugriff (PDF)

Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay

Free radical research, 2008-05, Vol.42 (5), p.435-441

2008

Volltextzugriff (PDF)

Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria

Cardiovascular toxicology, 2003, Vol.3 (2), p.89-100

2003

Volltextzugriff (PDF)

The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin

Cardiovascular toxicology, 2013-03, Vol.13 (1), p.33-47

2013

Volltextzugriff (PDF)

Deferiprone protects against doxorubicin-induced myocyte cytotoxicity

Free radical biology & medicine, 2002-07, Vol.33 (2), p.266-275

2002

Volltextzugriff (PDF)

High-throughput fluorescence flow-injection topoisomerase II inhibition assay

Journal of chromatography. B, Biomedical sciences and applications, 2001-09, Vol.760 (2), p.263-269

2001

Volltextzugriff (PDF)

The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells

Free radical research, 2006-09, Vol.40 (9), p.974-978

2006

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Aktive Filter

ThemaPharmacology & Pharmacy

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(69)

Sprache

Englisch
(69)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Life Sciences & Biomedicine
(57)
Animals
(36)
Biochemistry & Molecular Biology
(36)
Humans
(24)
Kinetics
(23)
Doxorubicin
(19)
Iron
(19)
Rats
(19)
Biological And Medical Sciences
(18)
Rats, Sprague-Dawley
(18)
Chemistry
(15)
Oxidation-Reduction
(14)
Physical Sciences
(14)
Cardiotoxicity
(13)
Electron Spin Resonance Spectroscopy
(13)
K562 Cells
(13)
Razoxane - Pharmacology
(13)
Biophysics
(12)
Dexrazoxane
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib

Evaluation of Nitrobenzyl Derivatives of Camptothecin as Anti-Cancer Agents and Potential Hypoxia Targeting Prodrugs

Disulfiram is a slow-binding partial noncompetitive inhibitor of 20S proteasome activity

Mechanisms of Myocyte Cytotoxicity Induced by the Multikinase Inhibitor Sorafenib

Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib

The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II)

Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs

The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity

Molecular mechanisms of the biological activity of the anticancer drug elesclomol and its complexes with Cu(II), Ni(II) and Pt(II)

Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F

Total Synthesis of Isoprekinamycin: Structural Evidence for Enhanced Diazonium Ion Character and Growth Inhibitory Activity toward Cancer Cells

Dexrazoxane use in the prevention of anthracycline extravasation injury

Expression of a stress‐induced hemoglobin affects NO levels produced by alfalfa root cultures under hypoxic stress

Class-1 hemoglobins, nitrate and NO levels in anoxic maize cell-suspension cultures

Cadmium is a catalytic inhibitor of DNA topoisomerase II

Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?

The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin

The intracellular iron sensor calcein is catalytically oxidatively degraded by iron(II) in a hydrogen peroxide-dependent reaction

The iron chelator Dp44mT does not protect myocytes against doxorubicin

Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay

Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria

The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin

Deferiprone protects against doxorubicin-induced myocyte cytotoxicity

High-throughput fluorescence flow-injection topoisomerase II inhibition assay

The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells

Aktive Filter

Suchergebnisse filtern